Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Falk

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Resuscitation|April 26, 2019
Cut-off values of serum potassium and core temperature at hospital admission for extracorporeal rewarming of avalanche victims in cardiac arrest: A retrospective multi-centre studyHermann Brugger, Pierre Bouzat, Mathieu Pasquier, et al.
Oncotarget|February 21, 2020
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCJulia Roeper, Markus Falk, Athena Chalaris-Rißmann, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor SpecimensJudith N Müller, Markus Falk, Jatin Talwar, et al.
Cancers|July 1, 2020
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung CancerStefanie Schatz, Markus Falk, Balázs Jóri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyMarcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
JAMA|October 8, 2025
Respiratory Gas Shifts to Delay Asphyxiation in Critical Avalanche Burial: A Randomized Clinical TrialFrederik Eisendle, Giulia Roveri, Simon Rauch, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Cancers|July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical ValidationEva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Resuscitation|April 26, 2019
Cut-off values of serum potassium and core temperature at hospital admission for extracorporeal rewarming of avalanche victims in cardiac arrest: A retrospective multi-centre studyHermann Brugger, Pierre Bouzat, Mathieu Pasquier, et al.
Oncotarget|February 21, 2020
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCJulia Roeper, Markus Falk, Athena Chalaris-Rißmann, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor SpecimensJudith N Müller, Markus Falk, Jatin Talwar, et al.
Cancers|July 1, 2020
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung CancerStefanie Schatz, Markus Falk, Balázs Jóri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyMarcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
JAMA|October 8, 2025
Respiratory Gas Shifts to Delay Asphyxiation in Critical Avalanche Burial: A Randomized Clinical TrialFrederik Eisendle, Giulia Roveri, Simon Rauch, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Cancers|July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical ValidationEva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
Pageof 7